Home  »  Market Insights   »  Quidel Corp. (QDEL) Stock on the Rise Following Pr...

Quidel Corp. (QDEL) Stock on the Rise Following Promising Preliminary Financial Report for Q3 2021

Quidel Corp. (QDEL) stock prices were up by 0.72% as of the market closing on October 7th, 2021. This brought the price per share up to USD$136.21 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 6.82%, bringing it up to USD$145.50.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Promising Revenue Report

In their preliminary results for the third quarter of fiscal 2021, QDEL stock announced expected revenues in the range of USD$505 million and USD$510 million. This marks a 6% to 7% improvement from the numbers reported in the prior year quarter. the 2021 quarter saw the company ship more than 45 million SARS tests, representing an increase of 135% as compared to shipments over the third quarter of fiscal 2020. Covid-19 revenues for the third quarter of fiscal 2021 are expected to be roughly USD$406 million. This is an improvement from the USD$375.7 million reported for the prior year quarter.

Increased Demand

The third quarter of fiscal 2021 saw QDEL stock reported a substantial increase in demand across several markets for its SARS category products. This is a result of the continued proliferation of Covid-19 infections due to the emergence of the highly transmissible Delta variant. The company was able to meet most of the demand at various points of care, including to consumers in stores and online, which resulted in driving product sales that were better than expected. The company’s ability to meet demand stems from its successful strategic investments made toward building out its professional and retail channels over the course of the first half of fiscal 2021.

QDEL Stock Secures Contract

In addition to the increase in professional and over the counter demand, QDEL stock also secured a 12-month contract. The contract is for the supplying of up to 51.2 million Quick Vue At-Home OTC Covid-19 rapid antigen tests to the federal government. The contract is expected to be worth USD$284 million, with order quantities from the government yet to be confirmed. Nevertheless, this award validates the company’s belief that a decentralized rapid antigen testing regiment that uses high-quality tests would be a critical tool to manage the spread of the coronavirus.

Future Outlook for QDEL Stock

QDEL stock is poised to capitalize on the expanded scope of opportunities afforded to it from the momentum generated over fiscal 2021. The company is keen to spearhead the accelerated proliferation of its proprietary healthcare solutions. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate consistent and organic growth in shareholder value over the long term.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam